Jon Napitupulu

Aztiq Pharma Partners has consolidated its stake in Alvotech through an internal transfer of 2,701,617 shares at USD 4.74...

Ligand Pharmaceuticals reported a decisive acceleration in its royalty-driven model, with full-year 2025 royalty revenue up 48% to $161...

Rhythm Pharmaceuticals reported fourth-quarter 2025 net product revenue of $57.3 million and set a near-term regulatory catalyst: a March...

Indivior posted record quarterly and full-year performance anchored by Sublocade, its long-acting buprenorphine injection for opioid use disorder. Total...

C4 Therapeutics has dosed the first patient in MOMENTUM, a Phase 2 study of the IKZF1/3 molecular glue degrader...

Kymera Therapeutics closed 2025 with two Phase 2b trials underway for KT-621, its first-in-class oral STAT6 degrader, in atopic...

argenx reported a breakout 2025: $4.2 billion in global product net sales for the year, up 90% year over...

Recursion reported fourth quarter and full-year 2025 results with a pivotal operational milestone: the company delivered its first AI-enabled...

Cardiff Oncology reported a positive randomized phase 2 readout in first-line RAS-mutated metastatic colorectal cancer, selecting the 30 mg...

Supernus Pharmaceuticals posted record fourth-quarter and full-year 2025 revenues, buoyed by newer CNS assets and the integration of Sage...